IMCR Immunocore Holdings plc

IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.

The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Immunocore Holdings plc has reported past second-quarter 2026 results showing revenue of US$115.93 million, with net loss narrowing to US$0.808 million, while first-half 2026 revenue reached US$222.60 million and shifted from a prior-period loss to net income of US$12.16 million. Alongside these figures, management highlighted Kimtrak’s first-half net revenue of US$223 million and five-year survival data in metastatic uveal melanoma, underscoring the therapy’s clinical and commercial...

Immunocore (NASDAQ:IMCR) reported continued growth for KIMMTRAK in the second quarter and first half of 2026, while advancing three late-stage melanoma trials and early-stage programs in oncology, HIV and Type 1 diabetes. The company recorded $223 million in KIMMTRAK net sales during the first half

Immunocore reports 16% revenue growth for Kimtrak, advances three Phase 3 trials, and maintains a robust $880 million cash position.

Immunocore reports robust first-half revenue, advances multiple Phase 3 trials, and maintains a strong cash position despite expected headwinds.

Immunocore Holdings (NasdaqGS:IMCR) has drawn fresh attention after a recent move in its share price, with the stock up around 21.6% over the past month and 6.2% in the past 3 months. See our latest analysis for Immunocore Holdings. That short term strength, including a 21.6% 1 month share price return and 6.7% 7 day share price return at a latest share price of $33.78, contrasts with a 1 year total shareholder return that is down 2.3% and a 3 year total shareholder return that is down 47.3%...

ATAI completes dosing in the phase IIb Elumina study of VLS-01 for treatment-resistant depression, with top-line efficacy and safety data due in fourth-quarter 2026.

TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.

NBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.